Mode
Text Size
Log in / Sign up
N/A N=2,046 Randomized Triple-blind Treatment

Learning Alerts for Acute Kidney Injury

Acute Kidney Injury

Enrolled (actual)
2,046
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death — 190; 193 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Alert (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Aug 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death
190; 193
SECONDARY
14-day Mortality
72; 58
SECONDARY
Inpatient Mortality
169; 185
SECONDARY
14-day Dialysis
38; 37
SECONDARY
Inpatient Dialysis
39; 41
SECONDARY
Discharge on Dialysis
28; 22
SECONDARY
Progression to Stage 2 AKI
91; 103
SECONDARY
Progression to Stage 3 AKI
72; 66
SECONDARY
Duration of AKI
26.9; 27.7
SECONDARY
30 Day Readmission Rate
123; 187
SECONDARY
Index Hospitalization Cost
SECONDARY
Chart Documentation of AKI
442; 505
SECONDARY
Proportion of AKI "Best Practices" Achieved Per Subject During Index Hospitalization
.6; .6

Summary

The primary objective of this study is to determine whether the use of uplift (also known as Conditional Average Treatment Effect - CATE) modeling to empirically identify patients expected to benefit the most from AKI alerting and to target AKI alerts to these patients will reduce the rates of AKI progression, dialysis, and mortality.

Eligibility Criteria

Inclusion Criteria

  • Adults ≥ 18 years
  • Admitted to a participating hospital
  • Has AKI as defined by creatinine criteria:
  • 0.3 mg/dl increase in inpatient serum creatinine over 48 hours OR
  • 50% relative increase in inpatient serum creatinine over 7 days

Exclusion Criteria

  • Dialysis order prior to AKI onset
  • Initial creatinine ≥ 4.0 mg/dl
  • Prior admission in which patient was randomized
  • Admission to hospice service or comfort measures only order
  • ESKD diagnosis code
  • Kidney transplant within six months
  • Opted out of electronic health record research
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02786277). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search